Functional loss of a noncanonical BCOR–PRC1.1 complex accelerates SHH-driven medulloblastoma formation

Lena M. Kutscher,^{1,2,16} Konstantin Okonechnikov,^{1,2,16} Nadja V. Batora,^{1,2,16} Jessica Clark,^{1,2} Patricia B.G. Silva,^{1,2} Mikaella Vouri,^{1,2} Sjoerd van Rijn,^{1,2} Laura Sieber,^{1,2} Britta Statz,^{1,2} Micah D. Gearhart,³ Ryo Shiraishi,⁴ Norman Mack,^{1,2} Brent A. Orr,⁵ Andrey Korshunov,^{6,7} Brian L. Gudenat,⁸ Kyle S. Smith,⁸ Audrey L. Mercier,^{9,10} Olivier Ayrault,^{9,10} Mikio Hoshino,⁴ Marcel Kool,^{1,2,11} Katja von Hoff,¹² Norbert Graf,¹³ Gudrun Fleischhack,¹⁴ Vivian J. Bardwell,³ Stefan M. Pfister,^{1,2,15} Paul A. Northcott,⁸ and Daisuke Kawauchi^{1,2,4}

¹Hopp-Children's Cancer Center Heidelberg (KiTZ), 69120 Heidelberg, Germany; ²Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), 69120 Heidelberg, Germany; ³Department of Genetics, Cell Biology, and Development, Masonic Cancer Center, Developmental Biology Center, University of Minnesota, Minneapolis, Minnesota 55455, USA; ⁴Department of Biochemistry and Cellular Biology, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP), Tokyo 187-0031, Japan; ⁵Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA; ⁶Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; ⁷Department of Neuropathology, Heidelberg University Hospital, 69120 Heidelberg, Germany; ⁸Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA; ⁹Institut Curie, PSL Research University, UMR 3347, Centre National de la Recherche Scientifique (CNRS), U1021, Institut National de la Santé et de la Recherche Médicale (INSERM), Orsay 91405, France; ¹⁰Université Paris Sud, Université, UMR 3347, CNRS, U1021, INSERM, Orsay 91405, France; ¹¹Princess Maxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands; ¹²Department for Paediatric Oncology and Haematology, Charité University Medicine, 13354 Berlin, Germany; ¹³Department for Pediatric Oncology and Hematology, Universitätsklinikum des Saarlandes, 66421 Homburg, Germany; ¹⁴Pediatric Haematology and Oncology, Pediatrics III, University Hospital of Essen, 45147 Essen, Germany; ¹⁵Department of Pediatric Hematology and Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany

Medulloblastoma is a malignant childhood brain tumor arising from the developing cerebellum. In Sonic Hedgehog (SHH) subgroup medulloblastoma, aberrant activation of SHH signaling causes increased proliferation of granule neuron progenitors (GNPs), and predisposes these cells to tumorigenesis. A second, cooperating genetic hit is often required to push these hyperplastic cells to malignancy and confer mutation-specific characteristics associated with oncogenic signaling. Somatic loss-of-function mutations of the transcriptional corepressor *BCOR* are recurrent and enriched in SHH medulloblastoma. To investigate *BCOR* as a putative tumor suppressor, we used a genetically engineered mouse model to delete exons 9/10 of *Bcor* (*Bcor*^{ΔE9–10}) in GNPs during development. This mutation leads to reduced expression of C-terminally truncated BCOR (*BCOR*^{ΔE9–10}). While *Bcor*^{ΔE9–10} alone did not promote tumorigenesis or affect GNP differentiation, *Bcor*^{ΔE9–10} combined with loss of the SHH receptor gene *Ptch1* resulted in fully penetrant medulloblastomas. In *Ptch1*^{+/-};*Bcor*^{ΔE9–10} tumors, the growth factor gene *Igf2* was aberrantly up-regulated, and ectopic *Igf2* overexpression was sufficient to drive tumorigenesis in *Ptch1*^{+/-} GNPs. BCOR directly regulates *Igf2*, likely through the PRC1.1 complex; the repressive histone mark H2AK119Ub is decreased at the *Igf2* promoter in *Ptch1*^{+/-};*Bcor*^{ΔE9–10} tumors. Overall, our data suggests that BCOR–PRC1.1 disruption leads to *Igf2* overexpression, which transforms preneoplastic cells to malignant tumors.

[**Keywords:** BCOR; brain tumor; cerebellar granule cells; PRC1.1 complex; medulloblastoma; mouse model]

Supplemental material is available for this article.

Received February 11, 2020; revised version accepted July 10, 2020.

¹⁶These authors contributed equally to this work.

Corresponding authors: d.kawauchi@ncnp.go.jp; paul.northcott@stjude.org

Article published online ahead of print. Article and publication date are online at <http://www.genesdev.org/cgi/doi/10.1101/gad.337584.120>.

© 2020 Kutscher et al. This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see <http://genesdev.cshlp.org/site/misc/terms.xhtml>). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International) as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

Pediatric cancer is the number one cause of disease-related death in children, and brain tumors are the most common pediatric solid tumor (Udaka and Packer 2018). Medulloblastoma is a malignant embryonal tumor of the cerebellum that is comprised of at least four biologically and clinically distinct molecular subgroups (Northcott et al. 2012). One subgroup, Sonic Hedgehog (SHH) medulloblastoma, arises through genetic alterations that activate the SHH signaling pathway, including mutations in the SHH receptor gene *PTCH1*, activating mutations in the transmembrane protein-coding gene *Smoothed* (*SMO*), mutations in the negative regulator gene *SUFU*, or amplification of the transcription factor genes *GLI2* or *MYCN* (Hahn et al. 1996; Johnson et al. 1996; Goodrich et al. 1997; Kenney et al. 2003; Kool et al. 2014).

While constitutive activation of SHH signaling is required for SHH medulloblastoma formation, studies in mice have demonstrated that additional genetic hits are required for the malignant transformation of cerebellar granule neuron progenitors (GNPs) in *Ptch1* heterozygous animals (Oliver et al. 2005; Kessler et al. 2009; Tamayo-Orrego et al. 2016; Tamayo-Orrego and Charron 2019). Depending on the nature of these mutations, the molecular and cellular properties of the tumor may change (Vogelstein and Kinzler 1993). More importantly, understanding how these cooperating mutations contribute to malignancy may reveal new therapeutic opportunities for affected patients.

We and others previously identified recurrent inactivating mutations targeting the transcriptional corepressor gene *BCOR* in SHH medulloblastoma (Kool et al. 2014; Northcott et al. 2017; Waszak et al. 2020), but the mechanism(s) underlying *BCOR*-associated medulloblastoma formation remain unclear. *BCOR* aberrations are implicated in a variety of pediatric cancers, including acute myeloid leukemia, retinoblastoma, sarcomas, glioblastomas, and CNS high-grade neuroepithelial tumor with *BCOR* alteration (CNS-HGNET-*BCOR*) (Grossmann et al. 2011; Astolfi et al. 2015; Kooi et al. 2016; Sturm et al. 2016; Mackay et al. 2017; Santiago et al. 2017). Altogether, deregulation of *BCOR* is implicated in at least 18 different tumor histotypes of pediatric cancer (Astolfi et al. 2019), demonstrating the urgency in understanding the role(s) of *BCOR* in normal cellular processes and tumorigenesis.

BCOR was originally identified based on its interaction with the zinc finger transcription factor *BCL6* and subsequently shown to be a component of a noncanonical Polycomb-repressive complex (PRC1.1) (Huynh et al. 2000; Gearhart et al. 2006; Cao et al. 2016). *BCL6* can recruit *BCOR* to DNA via the *BCL6*-interacting motif found in the N-terminal half of *BCOR* (Fig. 1A; Ghetu et al. 2008). The C terminus of *BCOR* contains nonankyrin repeats, ankyrin repeats, and the PUFD, which binds the Polycomb group protein PCGF1 (Fig. 1A; Junco et al. 2013). These regions and their associated interacting partners are conserved in *BCOR* in mice (Huynh et al. 2000; Wamstad and Bardwell 2007; Wamstad et al. 2008).

BCL6 has been implicated previously in cerebellar development in mice (Tiberi et al. 2014). Overexpression of human *BCL6* suppresses medulloblastoma formation

in vivo in mice, perhaps through interaction with *BCOR* at *Gli1/Gli2* promoters (Tiberi et al. 2014), although recurrent *BCL6* mutations have not been identified in SHH medulloblastoma patient samples. While the interaction between *BCOR* and *BCL6* may be one mode of *BCOR*-mediated tumor suppression, there are also truncating mutations in *BCOR* in human tumors that occur after the *BCL6* binding motif (Fig. 1A; Kool et al. 2014; Northcott et al. 2017; Waszak et al. 2020), suggesting that there may be other modes of *BCOR*-mediated tumor suppression. C-terminal truncation of the PUFD may lead to an inability to recruit PCGF1, which together with RING1B, ubiquitinates histone H2A at lysine 119 (H2AK119Ub) to repress transcription of target genes (Gearhart et al. 2006). Therefore, we set out to determine whether *BCOR* function within the PRC1.1 complex may be one mechanism of tumor suppression in SHH medulloblastoma.

Here we show that genetic ablation of exons 9 and 10 of *Bcor* (*Bcor*^{ΔE9–10}) in GNPs does not disrupt granule neuron differentiation in mice. Instead, *Bcor*^{ΔE9–10} cooperates with inactivation of *Ptch1* to potentiate aggressive medulloblastoma formation. *BCOR* occupies the *Igf2* promoter region in *Ptch1*^{+/-} tumors, and chromatin occupancy is greatly reduced in *Ptch1*^{+/-}; *Bcor*^{ΔE9–10} tumors. This reduction is strongly associated with aberrant up-regulation of *Igf2* in these tumors to drive tumorigenesis. Additionally, *BCOR*^{ΔE9–10} no longer binds PCGF1 or RING1B, the catalytic subunit of the PRC1.1 complex, which leads to a global reduction of the repressive histone mark H2AK119Ub, and a reduction of this mark specifically at the *Igf2* promoter, compared with *Ptch1*^{+/-} tumors. Our work demonstrates that loss of the C terminus of *BCOR* disrupts PRC1.1 complex function to drive SHH medulloblastoma formation in mice.

Results

BCOR is recurrently comutated with members of the SHH pathway in pediatric SHH medulloblastoma

We and others previously identified *BCOR* as recurrently mutated or deleted in 8% of pediatric SHH medulloblastomas (Kool et al. 2014; Northcott et al. 2017; Waszak et al. 2020). We mapped the identified *BCOR* mutations from these published data sets to the *BCOR* coding sequence (Fig. 1A) and determined that the C-terminal PUFD may be absent due to the introduction of premature STOP codons in nine out of 13 cases (Table 1). In the majority of cases (10 out of 13), *BCOR* is comutated with members of the SHH pathway, including *PTCH1* (5/10), *GLI2* (one out of 10), *SMO* (two out of 10), *SUFU* (two out of 10), or *SHH* gene amplification (one out of 10). *BCOR* is an X-linked gene, and the majority of affected patients were male (nine out of 13). Given its potential as a cooperating mutation in SHH medulloblastoma formation, we investigated the functional relevance of *BCOR* mutations during normal cerebellar development and tumorigenesis, specifically focusing on a potential role of the C-terminal domain in tumor suppression.

Figure 1. Conditional *Bcor* mouse model is an appropriate model for human *BCOR* mutations. (A) *BCOR* mutations identified in pediatric medulloblastoma samples. (B) BCL6-binding domain; (NonAnkRep) nonankyrin repeats; (Ank) Ankyrin repeats; (PUFD) PCGF Ub-like fold discriminator domain; (maroon lollipop) nonsense mutation; (pink lollipop) frame shift mutation; (green lollipop) point mutation. (B,C) In situ hybridization (dark blue) of antisense *Bcor* probe (B) and *Ccnd2* probe (C) at P7 in Bl6N wild-type (WT) mice. Scale bar, 50 μ m. (oEGL) Outer external granule layer; (iEGL) inner external granule layer; (ML) molecular layer. Nuclei counterstained with methyl green. (D,E) In situ hybridization of antisense *Bcor* probe at P28 in WT (D) and in *Ptch1*^{+/-} (E) mice. Scale bar, 200 μ m. (IGL) Inner granule layer; (ML) molecular layer; (PNC) preneoplastic cells. Nuclei counterstained with methyl green. (F) Increased magnification of preneoplastic region in E. Scale bar, 100 μ m. (G, left) Immunohistochemistry using an anti-BCOR antibody (pink) at P7. (Right) DAPI stains nuclei in blue (merged). Maximum intensity projection of 16- μ m-thick cerebellar section. Scale bar, 10 μ m. (H) Immunohistochemistry using an anti-BCOR antibody (pink) and an anti-pH3 antibody (yellow) at P28 in the preneoplastic lesion of *Ptch1*^{+/-} animals. DAPI stains nuclei in blue. Single z-slice. Scale bar, 100 μ m. (PNC) Preneoplastic cells; (IGL) inner granule layer. (I) Increased magnification of boxed region in H. Scale bar, 20 μ m. (J) Relative mRNA expression of *Bcor* and *Ccnd2* (quantitative PCR) of P7 granule neuron progenitors cultured in the absence (gray) or presence (blue) of Smoothened agonist (SAG). (* $P < 0.05$; *** $P < 0.001$, Student's *t*-test. Bars represent mean $\pm$ SEM. $N = 6$. (K) Location of LoxP sites in *Bcor*. Expression of Cre removes exons 9 and 10, and leads to an early translation stop. Color scheme for *Bcor* domains same as in A. (L) anti-BCOR Western blot of purified granule neuron progenitors in wild-type (*Atoh1-Cre* only) cells and in *Bcor*^{flxed/flxed} + *Atoh1-Cre* (*Bcor* ^{Δ E9-10}) cells. Anti-ACTIN was used as the loading control. See also Supplemental Figures S1 and S2.

Bcor is expressed in proliferating murine GNP

We first determined whether *Bcor* is normally expressed in developing cerebellar GNPs in mice, the cell of origin for SHH medulloblastoma (Schüller et al. 2008; Yang et al. 2008). Using RNA in situ hybridization (ISH), we found that *Bcor* is expressed at low levels in the outer external granule layer of the P7 cerebellum (Fig. 1B), in a similar domain as actively cycling cells (*Ccnd2*, Fig. 1C). After cerebellar development is complete, however, *Bcor* is no longer expressed (P28, Fig. 1D).

In mice heterozygous for the SHH receptor gene *Ptch1* (written as *Ptch1*^{+/-} here), preneoplastic lesions form in 85% of mice by P21, but the majority regress by P42 (Corcoran et al. 2008; Kessler et al. 2009). We found that *Bcor* is expressed in these preneoplastic lesions but not in adjacent normal tissue (Fig. 1E,F).

To determine whether BCOR protein is expressed in a similar manner, we performed immunohistochemistry using an anti-BCOR antibody. At P7, BCOR is detected in high levels in dividing GNPs (one to two cells per

Table 1. *BCOR* mutations in *SHH* medulloblastoma patient samples

BCOR mutation	Co-occurring alterations	Sex	Age (years)	Affymetrix	RNA-seq	Histology	Reference
P126 ^a	<i>SMO</i>	M	2	No	Yes	Unknown	Waszak et al. 2020
L279delX	<i>SHH</i> amp ^b	F	2	No	No	Desmoplastic	Kool et al. 2014
Y497delX	<i>SMO</i>	M	3	No	Yes	Desmoplastic	Northcott et al. 2017
A570 ^a	None ID'd	M	1	Yes	No	Unknown	Northcott et al. 2017
N668S	<i>PTCH1</i> ^b	F	43	No	No	Classic	Kool et al. 2014
E1001K	<i>SUFU, DDX3X, PTEN</i>	M	5	No	No	Unknown	Waszak et al. 2020
N1057 ^a	<i>PTCH1, DDX3X</i>	M	16	No	No	Unknown	Northcott et al. 2017
P1111S	None ID'd ^b	F	2	Yes	No	Desmoplastic	Kool et al. 2014
K1207 ^a	<i>DDX3X</i>	M	7	No	No	Classic	Northcott et al. 2017
Q1208 ^a	<i>SUFU, ZIC2</i>	M	1	No	No	Unknown	Northcott et al. 2017
S1358Y	<i>PTCH1, SMARCB1</i>	F	27	Yes	Yes	Unknown	Northcott et al. 2017
Y1384X	<i>PTCH1</i>	M	4	No	Yes	Unknown	Waszak et al. 2020
W1598X	<i>PTCH1, GLI2, PTEN, DDX3X</i>	M	25	No	No	Desmoplastic	Northcott et al. 2017

(delX) Deletion resulting in nonsense mutation.

^aFrameshift mutation. (X) Nonsense mutation; (M) male; (F) female; (None ID'd) none identified.^bPanel sequencing. (amp) Amplification; (unknown) histology type unknown/not available.

10⁴-μm² area), and at lower levels throughout the outer EGL (average number of BCOR⁺ cells in the EGL 36% ± 19%, *N* = 12 regions) (Fig. 1G; Supplemental Fig. S1A,B). At P28, we did not detect BCOR at appreciable levels in wild-type animals (Supplemental Fig. S1C), but we did detect BCOR protein in *Ptch1*^{+/-} preneoplastic lesions (Fig. 1H,I), with highest expression in mitotic cells (phospho-histone H3 [pH3]-positive). In some preneoplastic lesions, BCOR protein was detected in up to 100% of cells (average number of BCOR⁺ cells 62% ± 25%, *N* = 12 regions).

To determine the effect of proliferation on *Bcor* expression, we examined *Bcor* RNA levels in GNPs cultured with or without a Smoothed agonist (SAG) in vitro. *Bcor* expression is ~6× higher in proliferating GNPs (with SAG) compared with differentiated cells (without SAG) (Fig. 1J, *Ccnd2* as positive control). Taken together, the expression pattern demonstrates that *Bcor* is up-regulated in actively proliferating cells.

Mouse NIH/3T3 cells are sensitive to SHH signaling, which allows us to determine whether *Bcor* is regulated by SHH signaling, either directly or indirectly. We treated NIH/3T3 cells with SAG or DMSO control and found that while *Gli1* is significantly up-regulated after SAG treatment, *Bcor* levels remain unchanged (Supplemental Fig. S1D). These results suggest that *Gli1* and SHH signaling do not directly (or indirectly) regulate *Bcor*, and that instead *Bcor* expression seems to be associated with cell cycle states.

To further examine the likelihood of SHH-independent expression of *Bcor*, we examined mouse GLI1/GLI2 target genes using ChIP-Atlas (<http://chip-atlas.org>), a Web tool that predicts protein-specific gene regulation, based on the binding profiles of public chromatin immunoprecipitation (ChIP) sequencing data for a particular gene locus (Oki et al. 2018). Using this program, we did not detect GLI1 or GLI2 binding within ±10 kb of the transcriptional start site of *Bcor*. We also examined more closely the data from Lee et al. (2010), where GLI1 binding sites were

mapped by ChIP-seq in wild-type GNPs and in *Ptch1*-driven medulloblastoma. They also did not detect *Bcor* as a GLI1 target gene, supporting the idea that *Bcor* activation is independent of GLI-mediated SHH signaling pathway.

BCL6-related cerebellar functions are maintained in the *Bcor*^{ΔE9-10} mouse model

BCOR and its N-terminal interaction with BCL6 has been previously implicated in SHH medulloblastoma in mice (Tiberi et al. 2014). Using our mouse model, we sought to determine whether any BCL6-related functions of BCOR were disrupted, as this would allow us to distinguish the role of the C-terminal domain in BCOR-mediated tumor suppression, outside of BCL6-mediated processes. We were especially interested in this given the majority of BCOR mutations in SHH medulloblastoma are predicted to disrupt C-terminal function (Fig. 1A). To investigate the functional relevance of a C-terminal deletion of BCOR during GNP development and tumorigenesis, we used a genetically engineered mouse strain to generate Cre inducible excision of *Bcor* exons 9 and 10 in *Atoh1*-positive GNPs (*Bcor*^{ΔE9-10}) (Fig. 1K; Hamline et al. 2020). At the protein level, this excision results in reduced expression of a truncated BCOR protein (Fig. 1L).

We investigated whether BCL6-related functions were disrupted in our mouse model. We attempted to coimmunoprecipitate (co-IP) BCL6 using an anti-BCOR antibody in purified P7 GNPs, but we did not detect BCL6 by Western blot in either the input or the IP lanes. Therefore, we used a heterologous system to investigate whether BCOR^{ΔE9-10} interacts with BCL6. We overexpressed HA-tagged full-length mouse BCOR or HA-tagged mouse BCOR^{ΔE9-10} with mouse BCL6 in HEK293T cells and performed co-IP using bulk protein extract. We found that BCOR^{ΔE9-10} interacts with BCL6 in vitro (Supplemental Fig. S2A), suggesting that the BCL6 interacting motif of

BCOR^{ΔE9-10} may still be functional if these proteins are coexpressed in the same cells.

Next, we examined whether any known BCL6-related developmental functions are affected in vivo in our Bcor^{ΔE9-10} mouse model. *Bcl6* is required for timely GNP differentiation (Tiberi et al. 2014), so we first tested whether differentiation is affected in Bcor^{ΔE9-10} GNPs. In contrast to *Bcl6* knockout animals (Tiberi et al. 2014), we found that Bcor^{ΔE9-10} mice do not exhibit defects in GNP differentiation or migration (Supplemental Fig. S2), further suggesting that previously reported BCL6-related functions in the cerebellum are largely unaffected in our mouse model. We found no differences between wild-type and Bcor^{ΔE9-10} animals in the total number of GNP cells at P7 (PAX6-positive, Supplemental Fig. S2B–D) or proliferating cells (Ki67-positive) (Supplemental Fig. S2E–G). We found comparable numbers of NeuN⁺ cells between wild-type and Bcor^{ΔE9-10} cerebella at P7 (Supplemental Fig. S2H–J). We also found no differences in proliferation or cell cycle exit 2 h after a single dose of EdU at P7 (Supplemental Fig. S2K–P). We examined migration of granule neurons at P28 following a single EdU pulse at P7 and found no differences between wild-type and Bcor^{ΔE9-10} animals (Supplemental Fig. S2Q–U).

To further confirm that BCL6-dependent roles of BCOR are largely unaffected in Bcor^{ΔE9-10} GNPs, we examined expression of known BCL6/BCOR-regulated genes (Tiberi et al. 2014). Loss of *Bcl6* in cerebellar cells resulted in an increase in *Gli1* and *Gli2* expression, and both BCOR and BCL6 were bound at these promoter regions (Tiberi et al. 2014). To determine whether BCOR^{ΔE9-10} affects expression of these and other SHH-pathway related genes in GNPs, we isolated total RNA from wild-type and Bcor^{ΔE9-10} GNPs and evaluated target gene expression using qPCR. In contrast to *Bcl6* loss (Tiberi et al. 2014), loss of the region encoding the C-terminal domain of BCOR did not activate expression of *Gli1*, *Gli2*, *Ccnd1*, *Ptch1*, or *Mycn* (Supplemental Fig. S2V), suggesting that BCOR^{ΔE9-10} does not influence BCL6-related SHH signaling repression in GNPs. Taken together, our Bcor^{ΔE9-10} mouse model allows us to assess the role of BCOR in GNPs, and in particular the involvement of the C terminus and PRC1.1 in medulloblastoma formation.

Bcor^{ΔE9-10} significantly reduces latency and increases penetrance of Ptch1-associated medulloblastoma

Next, we examined whether Bcor^{ΔE9-10} affects tumor formation in conjunction with *Ptch1* inactivation. Deletion of the region encoding the C-terminal domain of BCOR in GNPs by itself did not promote medulloblastoma (Fig. 2A). Similar to previous studies (Goodrich et al. 1997), heterozygous mutations in *Ptch1* resulted in spontaneous medulloblastoma formation in 35% of animals, with a median latency of 179 d (Fig. 2A). In these mice, the second copy of *Ptch1* is inactivated, with additional secondary mutations in other genes (Tamayo-Orrego et al. 2016). Combining Bcor^{ΔE9-10} with *Ptch1* mutations resulted in tumorigenesis with 100% penetrance and a median latency of 75 d ($P < 0.0001$, log-rank [Mantel-

Cox] test) (Fig. 2A). There was a histological switch from classic in *Ptch1*^{+/-} tumors ($N = 3/3$) (Fig. 2B) to the more aggressive histological subtype, large cell anaplastic (LCA), in *Ptch1*^{+/-};Bcor^{ΔE9-10} tumors ($N = 3/3$) (Fig. 2C), although BCOR mutated human tumors typically exhibit classic or desmoplastic histology (Table 1). To confirm that *Ptch1*^{+/-};Bcor^{ΔE9-10} mouse tumor cells had higher tumorigenic potential, we transplanted 8×10^5 cells from either *Ptch1*^{+/-} tumors or *Ptch1*^{+/-};Bcor^{ΔE9-10} tumors into the cerebella of immunodeficient mice. *Ptch1*^{+/-};Bcor^{ΔE9-10} tumor cells reestablished tumors considerably faster than *Ptch1*^{+/-} tumor cells (median latency 26 d vs. 150 d, $P < 0.0001$, log-rank [Mantel-Cox] test) (Fig. 2D).

To determine whether Bcor^{ΔE9-10} drives early transformation events, we next examined the number of preneoplastic lesions in the cerebella of P28 mice. *Ptch1*^{+/-} animals carry a *lacZ* gene that disrupts one copy of the *Ptch1* locus, and preneoplastic cell clusters, where the *Ptch1* promoter is active, can be identified by β -galactosidase staining (Fig. 2E–H; Goodrich et al. 1997; Oliver et al. 2005). We determined that *Ptch1*^{+/-};Bcor^{ΔE9-10} cerebella have twice the number of the lesions compared with *Ptch1*^{+/-} cerebella alone ($N = 3$ cerebella per genotype, $P = 0.0232$, Student's *t*-test) (Fig. 2I). This result suggests that a greater proportion of GNPs continue to proliferate in the absence of full-length Bcor and *Ptch1* compared with *Ptch1* loss alone, increasing the likelihood of malignant transformation. Intriguingly, loss of *Ptch1* together with Bcor^{ΔE9-10} resulted in a decrease of SHH-related gene expression compared with *Ptch1* alone (P7 GNPs, Supplemental Fig. S2V), suggesting deregulation of alternative pathway(s) may be required to promote malignant transformation.

Igf2 is up-regulated in murine medulloblastomas

Based on our qPCR data (Supplemental Fig. S2V), SHH pathway genes are likely not the only drivers in *Ptch1*^{+/-};Bcor^{ΔE9-10} tumors. To identify alternative signaling pathways or genes that may contribute to tumorigenesis in this context, we used RNA sequencing to identify differentially expressed genes in *Ptch1*^{+/-};Bcor^{ΔE9-10} tumors compared with *Ptch1*^{+/-} tumors. Unsupervised clustering of transcriptome profiles demonstrated a clear difference between the tumor models (Supplemental Fig. S3A) and differential expression analysis revealed possible drivers (Supplemental Table S1).

We performed a gene ontology analysis on the differentially expressed genes using DAVID, focusing on biological processes and the KEGG pathway (Supplemental Table S2). We observed enrichment of various epigenetic activities, such as transcription regulation, and enrichment of cell proliferation pathways in the *Ptch1*^{+/-};Bcor^{ΔE9-10} tumors (Supplemental Table S2). The SHH pathway was not preferentially enriched, since likely both models depend on SHH signaling for tumorigenesis. We also found known cancer signaling pathways up-regulated in *Ptch1*^{+/-};Bcor^{ΔE9-10} tumors, including the HIPPO signaling pathway, MAPK pathway, and PI3K–Akt signaling pathway members (Supplemental Table S2).

Figure 2. *Bcor*^{ΔE9-10} significantly reduces latency and increases penetrance in *Ptch1*-driven medulloblastoma. (A) Survival curve of *Bcor*^{ΔE9-10} (black; N = 10), *Ptch1*^{+/-} (blue; N = 34), and *Ptch1*^{+/-};*Bcor*^{ΔE9-10} (red; N = 30) animals. (B,C) Representative H&E staining of *Ptch1*^{+/-} tumor (B) and *Ptch1*^{+/-};*Bcor*^{ΔE9-10} tumor (C). Notice typical round cells of classic histology (B) versus larger, pleomorphic nuclei of anaplastic histology (C). Scale bar, 10 μ m. (D) Survival curve of immunodeficient animals transplanted with 8×10^5 cells from *Ptch1*^{+/-} (blue; N = 13) and *Ptch1*^{+/-};*Bcor*^{ΔE9-10} (red; N = 13) tumors. (E,F) Representative examples of β -galactosidase staining (*lacZ* present in *Ptch1* locus) of P28 *Ptch1*^{+/-} cerebellum (E) and *Ptch1*^{+/-};*Bcor*^{ΔE9-10} cerebellum (F). (Red arrows) Premeoplastic lesions. (Inset) Magnified view of preneoplastic lesion. Scale bar, 1000 μ m. (G,H) Increased magnification of β -galactosidase staining similar to E and F. Premeoplastic lesions are noted by arrowheads and dotted lines. Scale bar, 500 μ m. (I) Quantification of the number of preneoplastic lesions in E and F. (*) $P < 0.05$, Student's *t*-test. Bars represent mean $\pm$ standard deviation. N = 3 cerebella per genotype.

Upon closer examination of the specific up-regulated genes, we focused on the growth factor *Igf2* as a potential tumorigenic driver in these tumors. *Igf2* was up-regulated ~20-fold in *Ptch1*^{+/-};*Bcor*^{ΔE9-10} tumors compared with *Ptch1*^{+/-} tumors (log₂FC: ~4.4, P -adj = 5.26×10^{-30}) (Fig. 3A). We also verified *Igf2* overexpression using Affymetrix microarray data from an additional cohort of samples (Supplemental Fig. S3B,C; Supplemental Table S1) and by performing qPCR on individual tumor samples (Fig. 3B). We found that IGF2 protein is expressed in *Ptch1*^{+/-};*Bcor*^{ΔE9-10} tumors, but not in P7 GNPs or *Ptch1*^{+/-} tumors (Fig. 3C).

Consistent with previous results (Corcoran et al. 2008), we did not detect *Igf2* expression in P7 GNPs in wild-type animals (Fig. 3B). There was also no aberrant expression of *Igf2* in P7 GNPs from either *Ptch1*^{+/-} or *Ptch1*^{+/-};*Bcor*^{ΔE9-10} mice by qPCR (Fig. 3B) or ISH (Fig. 3D,E). Additionally, we did not detect *Igf2* expression in *Ptch1*^{+/-} preneoplastic lesions or in *Ptch1*^{+/-} tumors (Fig. 3B,F,H; Supplemental Fig. S3D). Instead, aberrant *Igf2* expression was observed only in preneoplastic lesions of *Ptch1*^{+/-};*Bcor*^{ΔE9-10} animals (Fig. 3G) and in *Ptch1*^{+/-};*Bcor*^{ΔE9-10} tumors (Fig. 3B,I; Supplemental Fig. S3E), suggesting that inactivation of both *Ptch1* and *Bcor* are required for *Igf2* up-regulation.

IGF2 up-regulation is associated with BCOR mutations across multiple tumor types

To determine whether *Igf2* up-regulation is a conserved mechanism across species, we examined human medulloblastoma samples in which both genomic and transcriptomic data are available (Table 1; Kool et al. 2014; Northcott et al. 2017; Waszak et al. 2020). To investigate the transcriptional similarities between our mouse model and the ICGC medulloblastoma human tumor cohort (Northcott et al. 2017), we compared gene expression profiles between mouse and human tumors. Unsupervised clustering showed that our mouse models correspond to the SHH medulloblastoma subgroup, as expected (Supplemental Fig. S4A). We next focused only on the ICGC SHH medulloblastoma tumors and restricted our comparisons with the differentially expressed genes between *Ptch1*^{+/-} and *Ptch1*^{+/-};*Bcor*^{ΔE9-10} mouse models. We observed that *Ptch1*^{+/-};*Bcor*^{ΔE9-10} mouse tumors clustered near ICGC sample MB12 (Supplemental Fig. S4B). In this sample, there was a somatic mutation in *BCOR* (Y497delX) and a strong activation of *IGF2* (Fig. 3J).

The *BCOR* mutation in MB12 was confirmed using RNA-seq alignment data, and *BCOR* was highly expressed in this sample compared with other SHH

Figure 3. *Igf2* is overexpressed in *Ptch1*^{+/-}; *Bcor*^{ΔE9-10} tumors. (A) Volcano plot of differentially expressed genes between *Ptch1*^{+/-} and *Ptch1*^{+/-}; *Bcor*^{ΔE9-10} tumors. (B) Relative mRNA expression of *Igf2* (qPCR) of P7 GNPs (gray) in the indicated genotypes, *Ptch1*^{+/-} tumors (light blue), and *Ptch1*^{+/-}; *Bcor*^{ΔE9-10} tumors (dark blue). (n.s.) Not significant, Student's *t*-test. Bars of P7 GNPs represent mean ± SEM. *N* = 6 (WT, *Bcor*^{ΔE9-10} GNPs) or *N* = 8 (*Ptch1*^{+/-}, *Ptch1*^{+/-}; *Bcor*^{ΔE9-10} GNPs). (C) Anti-IGF2 Western blot of total protein extracts from P7 GNPs or tumor samples from the indicated genotypes. Anti-ACTIN was used as the loading control. (D–I) ISH of antisense *Igf2* probe (dark blue) in cerebella of animals from the indicated genotypes. (IGL) Inner granule layer; (EGL) external granule layer; (ML) molecular layer; (m) meninges; (PNC) preneoplastic cells. (D,E) P7. Scale bar, 100 μm. (F,G) P28. Scale bar, 200 μm. (H,I) Adult tumor. Scale bar, 100 μm. (J) Reads per kilobase of transcript per million mapped reads (RPKM) of *IGF2* from the ICGC cohort of SHH medulloblastoma samples (Northcott et al. 2017). Black samples are wild type at the *BCOR* locus. (K) Survival curve of immunodeficient animals transplanted with 1×10^6 *Ptch1*^{+/-} GNPs transduced with retrovirus overexpressing *eGFP* alone (black; *N* = 8), *Igf2-eGFP* (red; *N* = 7), or *Mycn-eGFP* (blue; *N* = 5). (L) Representative example of resulting *Igf2-eGFP* tumor from *K*. Scale bar, 2000 μm. (M) DAPI (top left; blue), *eGFP* (bottom left; green), and Ki67 (top right; magenta) immunohistochemistry of *Igf2-eGFP*-driven tumor. (IGL) Inner granule layer; (Cb) cerebellum. Scale bar, 100 μm. (N) Increased magnification of boxed region in *M*. Scale bar, 50 μm. (O) Representative histology sample of *Igf2-eGFP*-driven tumor. Scale bar, 10 μm. (P) Relative mRNA expression of *Igf2* in tumor cells from the indicated genotypes. Bars represent mean ± SEM. *N* = 7 for *Ptch1*^{+/-}, *N* = 4 for *Igf2-eGFP*, or *N* = 5 for *Ptch1*^{+/-}; *Bcor*^{ΔE9-10}. See also Supplemental Figures S3 and S4 and Supplemental Tables S1 and S2.

medulloblastoma samples (Supplemental Fig. S4C). This result suggests that the C-terminal domain of BCOR may indeed be affected, as a previously characterized *Bcor* gene trap allele that lacks the C terminus is similarly up-regulated (Wamstad et al. 2008). Using our Affymetrix data set, we also observed that the P1111S mutation was coincident with high *IGF2* overexpression, and A570* had moderate *IGF2* expression (Supplemental Fig. S4D).

While we also had one sample in the ICGC cohort with a *BCOR* missense mutation (S1358Y) that did not exhibit up-regulation of *IGF2* (Fig. 3J; Supplemental Fig. S4D), this mutation was located within the preankyrin repeats and may not negatively affect BCOR C-terminal function (Fig. 1A). *BCOR* expression in this tumor was also reduced compared with the rest of the cohort (Supplemental Fig. S4C), and the mutation was detected in only 2% of the RNA-seq reads.

While both the ICGC and Affymetrix cohorts contained *BCOR* mutated samples with high *IGF2* expression, we also examined three additional *BCOR* mutated samples from a recently published study (Waszak et al. 2020). For these three tumor samples, two had matching RNA-seq data (P126X and Y1384X). While we detected only the mutated reads for P126X in the RNA-seq data, wild-type *BCOR* transcript was detected in 14% of the reads in the Y1384X tumor sample. Nevertheless, neither of the tumors exhibited up-regulation of *IGF2*, suggesting that there are additional mechanisms of *BCOR*-associated tumorigenesis independent of *IGF2*.

Because the *BCOR* mutated samples only partially correlated with up-regulation of *IGF2* (three out of six samples), we examined other tumor subtypes with *BCOR* alterations. We focused on CNS-HGNET-*BCOR* tumors and clear cell sarcomas of the kidney (CCSK) tumors, as both of these tumor types have consistent alterations in the C-terminal domain of BCOR (internal tandem duplications [ITDs] in the PUFD [Paret et al. 2016; Wong et al. 2018]). Using a small cohort of CNS-HGNET-*BCOR* samples analyzed as part of our ongoing INFORM study (Worst et al. 2016), we confirmed that these tumors have high levels of *IGF2*, (Supplemental Fig. S4E), similar to published results (Vewinger et al. 2019). In three out of three CNS-HGNET-*BCOR* tumor samples, we detect up-regulation of *BCOR* itself (Supplemental Fig. S4F) and up-regulation of SHH pathway-related genes (Supplemental Fig. S4G,H), similar to published results (Paret et al. 2016).

In the five CCSK samples, we also detected high levels of *IGF2* (five out of five) (Supplemental Fig. S4E), up-regulation of *BCOR* (Supplemental Fig. S4F), and up-regulation of *PTCH1* and *GLI2* (Supplemental Fig. S4G,H), suggesting a role of SHH signaling in these tumors. In both cases, we compared expression of the target genes with group 3/4 medulloblastomas and SHH subgroup of medulloblastoma, all samples being wild type at the *BCOR* locus.

Igf2 overexpression is sufficient to drive tumorigenesis in *Ptch1*^{+/-} GNPs

To verify that *Igf2* overexpression is an oncogenic cofactor in SHH medulloblastoma formation (Corcoran et al.

2008), we transduced *Ptch1*^{+/-} GNPs ex vivo with retroviruses encoding *Igf2*-IRES-eGFP, *Mycn*-IRES-eGFP as a positive control, or eGFP alone as a negative control. We transplanted 1×10^6 transduced cells of each condition into the cerebella of adult immunocompromised mice. *Igf2*-transduced cells formed aggressive tumors that developed significantly faster than cells transduced with eGFP alone (100% penetrance; median survival = 54 d for *Igf2*, $P < 0.0001$, log-rank [Mantel-Cox] test) (Fig. 3K). Proliferating tumor cells (Ki67-positive) were eGFP-positive (Fig. 3L–N). Histologically, these tumors resembled *Ptch1*^{+/-}; *Bcor*^{ΔE9–10} tumors and all displayed an anaplastic histology (Fig. 3, cf. O [N = 3] and B,C).

Because *Igf2* overexpression accelerated tumorigenesis in this model, we examined the level of *Igf2* necessary for tumor induction and compared it with the expression level in the genetically engineered mouse models. We observed lower levels of *Igf2* expression in the *Igf2*-IRES-eGFP induced tumors compared with *Ptch1*^{+/-}; *Bcor*^{ΔE9–10} genetic tumors (Fig. 3P). While this difference in *Igf2* levels may be affected by the starting material used or mouse strain background, it also suggests the level of *Igf2* in *Ptch1*^{+/-}; *Bcor*^{ΔE9–10} tumors is more than sufficient to drive tumorigenesis.

BCOR^{ΔE9–10} fails to interact with members of the PRC1.1 complex, and the PUFD of BCOR is required for *Igf2* repression

The C-terminal domain of BCOR mediates its interaction with the PRC1.1 complex, a multi-protein complex that transfers ubiquitin to H2AK119 via the E3 ubiquitin ligase RING1B to repress target gene transcription (Wang et al. 2004, 2018). We tested whether the PRC1.1 complex is affected in *Ptch1*^{+/-}; *Bcor*^{ΔE9–10} tumors. Similar to previous studies (Tara et al. 2018), we found that *BCOR*^{ΔE9–10} no longer binds RING1B via co-IP in *Ptch1*^{+/-}; *Bcor*^{ΔE9–10} tumor samples, while full-length BCOR and RING1B co-IP in *Ptch1*^{+/-} tumor samples (Fig. 4A). We verified that PCGF1, a PRC1.1 complex member that directly interacts with the PUFD in BCOR, no longer interacts with *BCOR*^{ΔE9–10} either (Supplemental Fig. S5A).

In the genetically engineered mouse model, *BCOR*^{ΔE9–10} is missing both the PUFD, which is responsible for PCGF1 (and RING1B) binding (Wang et al. 2018), and the C-terminal ankyrin and nonankyrin repeats, which may interact with additional proteins outside of PRC1.1 (Fig. 1K), and therefore may also mediate tumor suppression independent of PRC1.1. To verify that loss of the PUFD alone, rather than the entire C terminus, is responsible for *Igf2* activation during medulloblastoma formation, we conducted in utero electroporation (IUE) experiments to test the role of the PUFD specifically in tumorigenesis. We generated a single plasmid carrying tandem sgRNAs targeting *Ptch1* (Zuckermann et al. 2015) and *Bcor* at exon 13 (107 nt upstream of the PUFD-coding sequence in the linker region, Supplemental Table S3) and Cre recombinase. We injected this plasmid in the fourth ventricle of E13.5 embryos that carry a single copy transgene expressing a Rosa26::Lox-Stop-Lox-Cas9-IRES-GFP

cassette (see the Materials and Methods for details) to generate *Ptch1* and *Ptch1*;*Bcor*^{ΔPUFD} medulloblastomas (Supplemental Fig. S5B–E). In *Ptch1*;*Bcor*^{ΔPUFD} IUE tumors, *Igf2* was overexpressed compared with *Ptch1* IUE control tumors (Fig. 4B), suggesting that loss of BCOR PUFD (Supplemental Table S3) aberrantly up-regulates *Igf2* transcription, likely via disruption of PRC1.1 complex assembly and targeting (Wang et al. 2018).

BCOR is bound at the Igf2 locus and represses gene transcription through H2AK119Ub

To determine whether BCOR is directly bound at the *Igf2* locus, we conducted BCOR ChIP in *Ptch1*^{+/-} and *Ptch1*^{+/-};*Bcor*^{ΔE9-10} tumor samples (see Materials and Methods for details). The BCOR antibody used was raised against a region common to BCOR and BCOR^{ΔE9-10} (encoded within exons 6–8) and thus detects both forms in Western blot (Fig. 1L) and ChIP. Global levels of BCOR binding were reduced but not completely lost in *Ptch1*^{+/-};*Bcor*^{ΔE9-10} tumors compared with *Ptch1*^{+/-} tumors (yellow panels, 2803/3093 peaks, Fig. 4C; Supplemental Table S4). There was also a small set of genes with increased binding in the *Ptch1*^{+/-};*Bcor*^{ΔE9-10} samples (290/3093 peaks). Importantly, we also detected 3890 peaks that were unchanged between all the replicates of the two samples, suggesting that BCOR^{ΔE9-10} is present.

Next, we examined the *Igf2* promoter region in *Ptch1*^{+/-} samples, and we found that BCOR is associated with chromatin in that region (Fig. 4D). We then checked the same region in *Ptch1*^{+/-};*Bcor*^{ΔE9-10} and discovered the BCOR peak is significantly reduced at the locus (Fig. 4D,E, Diff-Bind, *P*-adj < 0.05). Given that BCOR^{ΔE9-10} no longer binds to the catalytic subunit of the PRC1.1 (Fig. 4A), residual BCOR^{ΔE9-10} would only be capable of PRC1.1-independent functions.

If BCOR^{ΔE9-10} renders the PRC1.1 nonfunctional, then H2AK119Ub levels should be reduced compared with *Ptch1*^{+/-} controls. To test this hypothesis, we performed H2AK119Ub ChIP from chromatin prepared from the same tumor samples (see the Materials and Methods for details). We found that total levels of H2AK119Ub decreased at peaks where BCOR signal is significantly decreased (red panels, Fig. 4C), indicating that the enzymatic activity of PRC1.1 complex is indeed reduced at loci with less BCOR. At the *Igf2* locus, H2AK119Ub levels were significantly reduced in *Ptch1*^{+/-};*Bcor*^{ΔE9-10} tumor samples (Fig. 4D,F). We also called differential H2AK119Ub peaks between the two tumor types and then examined BCOR binding status, observing a similar effect (Supplemental Fig. S5F).

In P7 cerebellum, BCL6 and BCOR are located at promoter regions of *Gli1* and *Gli2* (Tiberi et al. 2014). We examined these same regions in our samples, and we found decreased BCOR binding at these sites (Supplemental Fig. S5G,H). However, H2AK119Ub levels were not significantly different at these regions, and there was no corresponding overexpression of *Gli1* or *Gli2* in *Ptch1*^{+/-};*Bcor*^{ΔE9-10} tumors (Supplemental Fig. S5G,H; Supplemental Table S1). These results suggest that the recruitment of BCOR by BCL6

is not required to maintain repression of *Gli1/Gli2*. The maintenance of H2AK119Ub at these loci suggests that other PRC1 complexes may compensate to prevent *Gli1/Gli2* overexpression.

Altogether, our results suggest that lack of full-length BCOR in *Ptch1*^{+/-};*Bcor*^{ΔE9-10} tumors leads to direct up-regulation of *Igf2*, and this aberrant *Igf2* expression is closely associated with reduced H2AK119Ub and a disrupted PRC1.1 complex (Fig. 4G), enhancing the incidence of malignant transformation during tumor progression.

Discussion

BCOR functions as a tumor suppressor in SHH medulloblastoma

BCOR is a large, multidomain protein implicated as a tumor suppressor in many pediatric cancers (Astolfi et al. 2019). In the case of medulloblastoma, BCOR is mutated with aberrant activation of SHH signaling. To determine how mutations in the C-terminal domain of BCOR may contribute to tumorigenesis, we used a *Ptch1* loss-of-function allele together with a conditional mouse *Bcor* allele. This allele, *Bcor*^{ΔE9-10}, is similar to some of the human BCOR mutations, where a C-terminally truncated protein, lacking the region required for interaction with PRC1.1 subunits, is predicted to be produced. *Bcor*^{ΔE9-10} must be at least a partial loss of function because we removed the domain critical for PRC1.1 interaction, and the levels of the truncated protein are significantly reduced in GNPs. However, we cannot exclude the possibility that the residual protein retains activity, but this activity is likely independent of PRC1.1.

It has been proposed previously that BCOR, in conjunction with BCL6 and SIRT1, represses *Gli1/Gli2* (Tiberi et al. 2014). Although binding of BCOR to the *Gli1/Gli2* loci is significantly reduced, *Gli1/Gli2* mRNA expression is normal in *Ptch1*^{+/-};*Bcor*^{ΔE9-10} tumors, indicating that the residual activity is sufficient to repress *Gli1/Gli2*. Thus, our results show that the BCOR tumor suppressor functions modeled here act independently of the previously described BCL6/BCOR/SIRT1 regulation of *Gli1/Gli2* (Tiberi et al. 2014). Furthermore, recurrent BCL6 mutations have not been identified in SHH medulloblastoma patient samples, suggesting that BCOR and its PRC1.1-related functions may be relevant to human tumor formation.

BCOR directly represses Igf2 via PRC1.1 complex-mediated H2AK119 ubiquitination

Our results suggest that BCOR directly represses *Igf2* transcription via interaction with other components of the PRC1.1 complex, which deposits H2AK119Ub repressive histone marks at the *Igf2* promoter. In *Ptch1*^{+/-} medulloblastoma, BCOR (and likely the entire PRC1.1 complex) is physically present at the *Igf2* promoter, K119 on histone H2A is ubiquitinated, and subsequently *Igf2* is repressed (no IGF2 protein is made). In *Ptch1*^{+/-};*Bcor*^{ΔE9-10}

Figure 4. The PUF Δ of BCOR is required for *Igf2* repression through H2AK119 Ubiquitination. (A) Coimmunoprecipitation of BCOR or BCOR Δ E9-10 with RING1B in *Ptch1*^{+/-} and *Ptch1*^{+/-}; *Bcor*^{ΔE9-10} tumor cells, respectively. (IgG) Immunoglobulin G control. Five percent input. (IP) Anti-RING1B. (Top blot) Anti-BCOR. (Bottom blot) Anti-RING1B. (B) Relative mRNA expression of *Igf2* in two *Ptch1* CRISPR tumors (gray), and two *Ptch1*; *Bcor*^{ΔPUFD} CRISPR-engineered tumors (blue). (C) Heat map of significant differentially bound peaks from BCOR chromatin immunoprecipitation (ChIP; yellow) between tumors from the indicated genotypes and the status of H2AK119Ub ChIP signals (red) within these genomic loci. (D) Combined BCOR and H2AK119Ub ChIP peaks in the indicated genotypes. Significantly different peak heights represented with yellow (BCOR) and red (H2AK119Ub) bars (BCOR peaks called first). *Igf2* locus is represented in blue. (E) Quantification of BCOR ChIP signal at *Igf2* locus. Differential peak calling with DiffBind. (*) *P*-adj < 0.05. (F) Quantification of H2AK119Ub ChIP signal at *Igf2* locus. Differential peak calling with DiffBind. (*) *P*-adj < 0.05. (G) Model of PRC1.1 complex disruption. (Open lollipops) Unmethylated CpG; (TSS) transcriptional start site; (yellow dots) H2AK119Ub histone marks; (red diamonds) H3K27me3 histone marks. See also Supplemental Tables S3 and S4 and Supplemental Figure S5.

medulloblastoma, however, BCOR protein levels are significantly decreased, and BCOR is no longer present at the *Igf2* promoter. As a result, the PRC1.1 complex cannot be recruited, so H2AK119Ub levels are lower. Since the repressor complex is no longer present, *Igf2* expression is de-repressed to yield IGF2 protein. We do not yet know the mechanism by which *Igf2* is activated downstream from BCOR loss, only that loss alleviates the repression. In the future, it will be interesting to investigate the mechanism(s) responsible for activating *Igf2* expression, as these may be relevant for treatment across different tumor types.

While our ChIP studies were conducted in progressive murine medulloblastomas, this mechanism likely occurs in preneoplastic lesions of *Ptch1*^{+/-} animals as well (given *Igf2* up-regulation in P28 *Ptch1*^{+/-}; *Bcor*^{ΔE9-10} cerebellum). 85% of *Ptch1*^{+/-} animals have preneoplastic lesions at P21, but only 15%–20% of animals develop progressive medulloblastoma (Corcoran et al. 2008; Kessler et al. 2009), suggesting that BCOR-PRC1.1 may function in preneoplastic cells to prevent aberrant *Igf2* overexpression. This hypothesis is further strengthened by the fact that IGF2 is necessary for late stage SHH medulloblastoma progression (Hahn et al. 2000; Corcoran et al. 2008). Nevertheless, no recurrent mutations of genes that encode components of PRC1.1 other than *BCOR* have been identified in SHH medulloblastoma. Perhaps these mutations influence cell viability in the developing brain, potentially leading to cell death rather than tumorigenesis.

Igf2 up-regulation was detected previously in *Ptch1*^{+/-} advanced stage medulloblastomas, but not in *Ptch1*^{+/-} preneoplastic lesions (Corcoran et al. 2008). We did not detect substantial up-regulation of *Igf2* in *Ptch1*^{+/-} tumors using *in situ* hybridization, but these differences may be explained by differences in methodology (DIG-labeled probes used in this study; ³⁵S-UTP-labeled probes used in Corcoran et al. 2008), since we did see occasional low levels of *Igf2* in *Ptch1*^{+/-} advanced medulloblastomas as detected by qPCR. Still, these levels are significantly lower compared with *Ptch1*^{+/-}; *Bcor*^{ΔE9-10} tumors.

If *Igf2* up-regulation is indeed required to push tumor-prone *Ptch1*^{+/-} cells toward tumorigenesis, our results complement these findings. Lack of a functioning BCOR-PRC1.1 complex leads to up-regulation of *Igf2* in preneoplastic lesions by P28 in *Ptch1*^{+/-} animals, which then pushes these cells toward fast-growing, lethal tumors. Few molecular mechanisms of transformation of preneoplastic lesions to malignant cells have been uncovered, and the present study unveiled *Igf2* overexpression in preneoplastic cells as one likely mechanism. This general mechanism explains why all *Ptch1*^{+/-}; *Bcor*^{ΔE9-10} mice, which express *Igf2* early-on in preneoplastic lesions, develop tumors with significantly reduced latency and dramatically increased penetrance compared with *Ptch1*^{+/-} mice.

From our RNA-seq and Affymetrix data, we also found that other cancer signaling pathways are up-regulated in the *Ptch1*^{+/-}; *Bcor*^{ΔE9-10} tumors, including HIPPO, MAPK, and PI3K-Akt signaling (Supplemental Tables S1, S2). These additional pathways may also contribute

to BCOR-driven malignancy and should be investigated in future studies. This is especially true given that in our human tumor samples, not all *BCOR* mutated medulloblastoma samples exhibit up-regulation of *IGF2*, suggesting involvement of additional mechanisms not explored in the current study. It will be interesting to determine whether these oncogenic pathways cooperate with *Igf2* and whether they are directly regulated by BCOR-PRC1.1.

Translatability to human tumors

We found that BCOR-PRC1.1 loss is associated with *Igf2* overexpression in a mouse model of SHH medulloblastoma, and we identified three out of six cases of *BCOR* mutated human SHH medulloblastoma samples where *IGF2* is up-regulated, suggesting that our finding may be generally applicable to some *BCOR* mutated tumor samples. However, caution is warranted when translating our findings to human tumors. First, we did not have sample-matched mutation and expression data for all of our patient tumor samples, so the power of our human findings is low. For the six we did have, only three showed up-regulation of *IGF2* compared with *BCOR* wild-type SHH medulloblastomas, suggesting this mechanism of tumorigenesis may be conserved only for certain mutation types.

In future studies involving human medulloblastoma samples, it will be important to fully understand the spectrum of *BCOR* mutations and how these may influence other oncogenic pathways. For example, in one of the samples that did not show *IGF2* up-regulation, *BCOR* carried only a point mutation (S1358Y). *BCOR* auto-represses itself, using its C-terminal domain (Wamstad et al. 2008). When the C-terminal domain is missing, *BCOR* expression increases (as seen in the MB12 sample). In S1358Y, *BCOR* expression remains low, suggesting its C-terminal repression may still be intact. The S1358Y point mutation is in a highly conserved amino acid, so the mode of *BCOR*-driven tumorigenesis in this sample likely differs from our mouse model, especially since *IGF2* was not up-regulated in this tumor.

IGF2 overexpression may be a general feature of *BCOR*-altered tumors

ITDs in the C terminus of *BCOR* have been reported not only in brain tumors, such as CNS-HGNET-*BCOR* tumors, but also CCSK and uterine sarcomas (Roy et al. 2015; Ueno-Yokohata et al. 2015; Mariño-Enriquez et al. 2018). Defects in the C terminus of *BCOR* are closely associated with high expression of *IGF2* in both CNS-HGNET-*BCOR* (Vewinger et al. 2019) and CCSKs (Schuster et al. 2003), suggesting that suppression of *IGF2* expression may be a general feature of *BCOR* function across tumor entities. Furthermore, both of the tumors exhibit aberrant activation of the SHH pathway (our studies, Paret et al. 2016), suggesting that both SHH pathway activation and *BCOR* aberrations cooperate to activate *IGF2*, similar to our *Ptch1*^{+/-}; *Bcor*^{ΔE9-10} mouse tumors.

As we uncovered, *Ptch1* mutated tumors and *Ptch1*^{+/-}; *Bcor*^{ΔE9-10} tumors have different tumorigenic properties, including penetrance, latency, and mechanism of tumorigenesis. If this association holds true across tumor types, patients with specific *BCOR* and *SHH*-related mutations may benefit from different treatment strategies compared with *SHH* medulloblastomas lacking *BCOR* mutations. More mechanistic studies are warranted to determine a possible link between the type of *BCOR* mutation and *IGF2* up-regulation. Our results also demonstrate the need to investigate the cooperating mutations for each subtype of medulloblastoma, and by extension, other tumor subtypes, to understand how these mutations contribute to malignant phenotypes.

Materials and methods

Animals

Bcor conditional knockout mice were generated by breeding of *Bcor*^{fl/fl} (*loxP* sites flanking exons 9 and 10) (Hamline et al. 2020) with *Atoh1-Cre* (JAX 011104) and *Ptch1* heterozygous mice (Goodrich et al. 1997). Genotyping primer sequences are available in Supplemental Table S5. All mice were bred on a C57BL/6N background. For tumor studies, only homozygous *Bcor*^{fl/fl} females or *Bcor*^{fl/y} males were used and referred to as *Bcor*^{ΔE9-10}. Of note, *Bcor*^{fl/+} females developed medulloblastoma at similar rates. For the in utero electroporation experiments, male *Rosa26-CAG-LSL-Cas9-P2A-EGFP* (JAX 024857) mice were crossed to CD-1 female animals purchased from Janvier and checked daily for vaginal plug. For transplantation experiments, Nod-scid IL2Ry^{null} (NSG; JAX 005557) were used. All animal experiments for this study were conducted according to the animal welfare regulations approved by the Animal Care and Use Committee of the National Institute of Neuroscience (NCNP) Japan (approval no. 2019028R2), and the responsible authorities in Baden-Württemberg, Germany (Regierungspräsidium Karlsruhe, approval nos. G-182/13, G-48/14, G-64/14, G-29/18, and G-23/19).

In utero electroporation In utero electroporation was performed as described previously (Zuckermann et al. 2015). For these experiments, we used a single px330 plasmid (Addgene #42230) modified to carry two sgRNA cassettes, and Cre recombinase coding sequence was used in place of Cas9. This plasmid together with a luciferase-encoding plasmid was injected into the fourth ventricle of E13.5 embryos and electroporated (30 V, 50 msec on, 950 msec off, five pulses). Positive pups were identified by luciferase signal at P7 and animals were monitored daily for the first neurological signs of medulloblastoma formation.

Orthotopic transplantation For retransplantation experiments, 8 × 10⁵ freshly isolated, purified tumor cells from *Ptch1*^{+/-} or *Ptch1*^{+/-}; *Bcor*^{ΔE9-10} animals were retransplanted to the cerebellum of NSG mice, according to published standard operating procedures (Brabetz et al. 2018), and animals were monitored daily for signs of tumor growth.

For *Igf2* overexpression studies, retroviruses were freshly generated as described previously (Kawauchi et al. 2012). P7 GNP isolated from *Ptch1*^{+/-} mice were cultured in vitro and transduced with MSCV-based retroviruses carrying *Igf2-IRES-eGFP*, *Mycn-IRES-eGFP* (positive control), or *eGFP* only (negative control). Two days later, infected GNPs were harvested and transplanted

to NSG mice (1 × 10⁶ cells per mouse) in the same manner as above.

Plasmids

A single px330 plasmid modified to carry Cre instead of Cas9 was generated to carry tandem cassettes for sgRNAs against *Ptch1* (CTGGCCGAAAGCGCCGCTG) and *Bcor* (ATAGAACTCC CAAGCGCCGC), using ASAP cloning protocol (Zuckermann et al. 2018). For *Ptch1*-only targeting construct, the sgRNA for *Bcor* was replaced with a control sgRNA (GCGACCAATACGC GAACGTC). For MSCV-based plasmids, the coding region for *Igf2*, *Mycn*, or empty vector was cloned using BamHI and XhoI sites. For co-IP plasmids in HEK293T cells, full-length *Bcor* cDNA or truncated *Bcor*^{ΔE9-10} cDNA was cloned with an N-terminal HA tag into pCAG vector using InFusion (Takara). pCMV-SPORT 6.1 with mouse *Bcl6* cDNA was purchased from Horizon Discovery (clone ID 6309948).

In situ hybridization

In situ hybridization (ISH) was performed as described previously (Kawauchi et al. 2006). Plasmids containing the coding region of *Bcor* (clone ID 6412868, Horizon Discovery), *Igf2* (clone ID 30013295, Horizon Discovery), and *Ccnd2* (5716186, Horizon Discovery) were linearized with XbaI, EcoRI, and AccI, respectively, and used to generate antisense RNA probes (DIG RNA labeling kit, Roche). Probes were hybridized on 10-μm-thick cryosections of the cerebellum or tumor samples of interest and counterstained with methyl green (Sigma). For expression pattern analysis, we checked three independent cerebella and all ISH results reported in this study were consistent in all three samples.

Histopathology and Immunostaining

For histopathology, samples of murine medulloblastomas (three tumors per genotype) were formalin-fixed, paraffin-embedded, and sectioned at 5 μm. The sections were stained with hematoxylin and eosin (H&E), and histological classifications were performed blinded to genotype.

Immunostaining was performed as described previously (Pajtker et al. 2019). Brains were harvested, fixed overnight in 4% paraformaldehyde (PFA) at 4°C, soaked in 30% sucrose in PBS overnight, and embedded in optimal cutting temperature (OCT) compound. Frozen 10-μm-thick sections were collected on Fisher Superfrost Plus slides using a cryostat. Sections were blocked for 30 min at room temperature with 10% normal donkey serum and incubated with primary antibody overnight at 4°C. After washing with PBST, sections were incubated with appropriate fluorescence secondary antibodies for 1 h at room temperature.

In the case of *BCOR* immunostaining, P7 brains were fixed at 1 h in 4% PFA and P28 brains were perfused with 4% PFA for 1 h, prior to soaking in 20% sucrose overnight. Sections were cut at 16 μm and permeabilized in 1% BSA + 0.4% Triton/PBS for 1 h at room temperature. Anti-*BCOR* antibody was incubated overnight at room temperature, and sections were washed with PBS prior to secondary antibody incubation.

Slides were mounted in ProLong Gold mountant (Invitrogen). Antibodies used are listed in Supplemental Table S5. Samples were counterstained with 300 nM DAPI. For quantification, we counted the number of positive cells in four 100-μm × 100-μm regions in three independent cerebella.

Quantitative PCR (qPCR)

GNP isolation was performed as previously described (Kawauchi et al. 2012). For in vitro studies, five million P7 GNPs were plated per well in a six-well plate and cultured for 48 h in the presence or absence of 200 nM smoothened agonist (Merck). RNA was extracted and cDNA was generated with SuperScript II kit (Invitrogen), according to the manufacturer's instructions. RNA and cDNA from tumor samples was generated similarly. Relative gene expression was compared with *Gapdh* in all experiments except Figures 3P and 4B, which was compared with the geometric mean of *Hrpt1*, *Rpl27*, and *Rer1*, and Supplemental Figure S1D, which was compared with 18s rRNA. All primer sequences are listed in Supplemental Table S5.

Western blotting

Protein was extracted from tissue or cells by addition of RIPA buffer (Sigma Aldrich) including complete protease inhibitor cocktail tablets (Roche) according to the manufacturer's instruction. Tissue was homogenized using the Tissue Master 125 homogenizer (OMNI International) or sonication after adding lysis buffer directly to the frozen sample. Cell lysates were vortexed three to four times every 10 min for a total of 30 min and were kept on ice in between. Lysates were centrifuged at 17,000g for 30 min at 4°C. Protein concentration of cell lysates was measured using Pierce BCA protein assay (Thermo Fisher Scientific), following the supplier's instructions. Primary antibodies are listed in Supplemental Table S5.

Co-IP

For interaction tests between RING1B and BCOR-FL / BCOR^{ΔE9-10} in mouse tumor samples, tumor cells were lysed in LB200 buffer with sonication. Anti-RING1B antibody was bound to IgG beads (1:500; Active Motif 39663) for 1 h at room temperature before applying 500 μg of the total cell lysate. Proteins were allowed to bind for 4 h at room temperature while rotating. After three wash steps with LB200 at room temperature, bound proteins were eluted in 2× SDS Laemmli buffer. Total elution was loaded on 4%–12% bis-Tris gradient gel (NuPAGE, Thermo Fisher Scientific) for downstream Western blotting.

X-gal whole-mount staining

X-gal staining was performed according to standard protocol. Brains were fixed in fresh 4% PFA / PBS for 1 h on ice, rinsed in Rinse Buffer (100 mM sodium phosphate at pH 7.3, 2 mM MgCl₂, 0.01% sodium deoxycholate, 0.02% [w/v] NP-40) three times for 10 min, followed by X-gal staining solution (5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 1 mg/mL X-gal in DMF) overnight at 37°C. After, brains were placed in 10% formalin and the number of preneoplastic lesions per cerebellum was quantified on a stereomicroscope (*N* = 3 per genotype).

Human tumor data analysis

The presence of *BCOR* mutations and indels was integrated from our previous medulloblastoma studies (Kool et al. 2014; Northcott et al. 2017; Waszak et al. 2020). These mutations were mapped onto NP_001116857.1. Where available, the *IGF2* gene expression was checked using RNA-seq data and Affymetrix data. Additionally, the *BCOR* somatic indel in sample MB12 was confirmed via RNA-seq alignment data. However, we only detected 2% of reads with the missense mutation in MB234.

FPKM gene expression values from selected tumor samples from INFORM were compared across entities (*BCOR*-WT group 3/4 medulloblastoma, *BCOR*-WT SHH medulloblastoma, CNS-HGNET-BCOR, and CCSK).

Mouse model gene expression analysis

RNA extraction Tissue was homogenized using the Tissue Master 125 homogenizer (OMNI International) and/or QIAshredder (Qiagen). RNA was extracted with RNeasy mini kit (Qiagen) following the supplier's instructions. For measurement of RNA quantity, ND1000 Spectrophotometer (NanoDrop Technologies) and/or Agilent 2100 Bioanalyzer was used. RNA-seq libraries were processed and sequenced on a HiSeq V4 (SR 50) by the DKFZ Genomics Core Facility.

RNA-seq analysis Transcriptome profiling (reads alignment to mm10 reference, quality control and gene expression counts computation) was performed using RNA sequencing data from *Ptch1*^{+/-} (*N* = 3) and *Ptch1*^{+/-}; *Bcor*^{ΔE9-10} (*N* = 3) medulloblastoma tumor models as described previously (Pajtler et al. 2019). Differentially expressed genes were detected using DESeq2 R package with applied limits: minimum *P*-adj 0.05, minimum log₂FC 0.5.

Additional extended transcriptome profiling from *Ptch1*^{+/-} (*N* = 5) and *Ptch1*^{+/-}; *Bcor*^{ΔE9-10} (*N* = 4) medulloblastoma SHH tumor models was performed with Affymetrix microarray 430v2. The differentially expressed genes were detected using Limma package (Ritchie et al. 2015) and sorted using *p*-adj limit for the top 1000 selection. DAVID gene ontology analysis was applied to the RNA-seq and Affymetrix data with a focus on biological processes and KEGG pathways.

The mouse tumor models were compared with the ICGC medulloblastoma RNA-seq cohort (*n* = 170). Ortholog selection was performed using the biomaRt R package via corresponding Ensembl database annotation. After batch effect adjustment with Combat (Leek et al. 2012), unsupervised clustering was performed with ward.D2 method on the top 500 most highly variable genes. To understand how the mouse models correspond to the human tumors, the ICGC cohort was restricted to the SHH subgroup only, and principal component analysis was performed on the combined batch effect adjusted gene expression counts, using the top 100 differentially expressed genes between *Ptch1*^{+/-} and *Ptch1*^{+/-}; *Bcor*^{ΔE9-10} tumors as the main input.

ChIP sequencing data analysis ChIP of H2AK119Ub (Cell Signaling Technologies) and BCOR (Vivian Bardwell Laboratory, University of Minnesota, anti-BCOR, RRID:AB_2716801) for *Ptch1*^{+/-}; *Bcor*^{ΔE9-10} and *Ptch1*^{+/-} tumor samples was performed by Active Motif. One sample of *Ptch1*^{+/-}; *Bcor*^{ΔE9-10} was discarded for outlier levels of *Igf2* revealed by RNA-seq after ChIP analysis. The sequencing reads representing H2AK119Ub and BCOR obtained from *Ptch1*^{+/-} (*N* = 4) and *Ptch1*^{+/-}; *Bcor*^{ΔE9-10} (*N* = 3) tumor model samples were aligned to the mm10 and *Drosophila* spike-in references using bwa 0.6.2. Next, the general quality control and read alignments statistics collection was performed using Qualimap v2.2 toolkit mode BAM QC (Okonechnikov et al. 2016). The coefficients from *Drosophila* spike-ins were computed based on the alignment statistics and applied to adjust to the reads distribution per sample. For peak calling Macs 1.4 tool (Zhang et al. 2008) was applied with corresponding background included as input and using *P*-value limit 1 × 10⁻⁹. Differential peaks were detected using DiffBind R package (Ross-Innes et al. 2012) with minimum *P*-adj of 0.05.

Acknowledgments

We thank Annarita Patrizi, Ana Banito, Mija Blattner-Johnson, and David T.W. Jones for their scientific input and discussions. Support by the GPCF Antibody Unit (Dr. Ilse Hofmann), DKFZ Light Microscopy Facility, and DKFZ Genomics Facility is gratefully acknowledged. This work was supported by a Deutsche Forschungsgemeinschaft grant (KA4472/1-1) and a grant from the Japan Agency for Medical Research and Development (AMED; JP20ck0106534h0001) to D.K., a Heinrich F.C. Behr Stipendium to N.V.B., and National Institutes of Health grants 5R01CA071540 and R01HD084459 to V.J.B.

Author contributions: N.V.B., P.A.N., and D.K. conceived the project. L.M.K., N.V.B., J.C., P.B.G.S., M.V., S.v.R., L.S., B.S., R.S., and D.K. conducted in vitro experiments. L.M.K., N.V.B., J.C., P.B.G.S., N.M., and D.K. performed animal experiments. K.O., B.L.G., and K.S.S. performed computational analysis. B.A.O. and A.K. performed histopathological analysis. M.D.G., V.J.B., S.M.P., A.L.M., O.A., M.K., M.H., K.v.H., N.G., and G.F. provided biomaterials and resources. L.M.K. wrote the original draft of the manuscript. L.M.K., K.O., N.V.B., M.D.G., V.J.B., S.M.P., P.A.N., and D.K. edited the manuscript. All authors reviewed and approved the manuscript. S.M.P., P.A.N., and D.K. supervised the project.

References

- Astolfi A, Melchionda F, Perotti D, Fois M, Indio V, Urbini M, Genovese CG, Collini P, Salfi N, Nantron M, et al. 2015. Whole transcriptome sequencing identifies BCOR internal tandem duplication as a common feature of clear cell sarcoma of the kidney. *Oncotarget* **6**: 40934–40939. doi:10.18632/oncotarget.5882
- Astolfi A, Fiore M, Melchionda F, Indio V, Bertuccio SN, Pession A. 2019. BCOR involvement in cancer. *Epigenomics* **11**: 835–855. doi:10.2217/epi-2018-0195
- Brabetz S, Leary SES, Gröbner SN, Nakamoto MW, Seker-Cin H, Girard EJ, Cole B, Strand AD, Bloom KL, Hovestadt V, et al. 2018. A biobank of patient-derived pediatric brain tumor models. *Nat Med* **24**: 1752–1761. doi:10.1038/s41591-018-0207-3
- Cao Q, Gearhart MD, Gery S, Shojaei S, Yang H, Sun H, Lin D-C, Bai J-W, Mead M, Zhao Z, et al. 2016. BCOR regulates myeloid cell proliferation and differentiation. *Leukemia* **30**: 1155–1165. doi:10.1038/leu.2016.2
- Corcoran RB, Bachar Raveh T, Barakat MT, Lee EY, Scott MP. 2008. *Insulin-like growth factor 2* is required for progression to advanced medulloblastoma in *patched1* heterozygous mice. *Cancer Res* **68**: 8788–8795. doi:10.1158/0008-5472.CAN-08-2135
- Gearhart MD, Corcoran CM, Wamstad JA, Bardwell VJ. 2006. Polycomb group and SCF ubiquitin ligases are found in a novel BCOR complex that is recruited to BCL6 targets. *Mol Cell Biol* **26**: 6880–6889. doi:10.1128/MCB.00630-06
- Ghetu AF, Corcoran CM, Cerchiatti L, Bardwell VJ, Melnick A, Privé GG. 2008. Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer. *Mol Cell* **29**: 384–391. doi:10.1016/j.molcel.2007.12.026
- Goodrich LV, Milenković L, Higgins KM, Scott MP. 1997. Altered neural cell fates and medulloblastoma in mouse *patched* mutants. *Science* **277**: 1109–1113. doi:10.1126/science.277.5329.1109
- Grossmann V, Tiacci E, Holmes AB, Kohlmann A, Martelli MP, Kern W, Spanhol-Rosseto A, Klein H-U, Dugas M, Schindela S, et al. 2011. Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. *Blood* **118**: 6153–6163. doi:10.1182/blood-2011-07-365320
- Hahn H, Wicking C, Zaphiropoulos PG, Gailani MR, Shanley S, Chidambaram A, Vorechovsky I, Holmberg E, Unden AB, Gillies S, et al. 1996. Mutations of the human homolog of *Drosophila patched* in the nevoid basal cell carcinoma syndrome. *Cell* **85**: 841–851. doi:10.1016/S0092-8674(00)81268-4
- Hahn H, Wojnowski L, Specht K, Kappler R, Calzada-Wack J, Potter D, Zimmer A, Müller U, Samson E, Quintanilla-Martinez L, et al. 2000. *Patched* target *Igf2* is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. *J Biol Chem* **275**: 28341–28344. doi:10.1074/jbc.C000352200
- Hamline MY, Corcoran CM, Wamstad JA, Miletich I, Feng J, Lohr JL, Hemberger M, Sharpe PT, Gearhart MD, Bardwell VJ. 2020. OFCD syndrome and extraembryonic defects are revealed by conditional mutation of the polycomb-group repressive complex 1.1 (PRC1.1) gene *Bcor*. *Dev Biol* doi:10.1016/j.ydbio.2020.06.013
- Huynh KD, Fischle W, Verdin E, Bardwell VJ. 2000. BCOR, a novel corepressor involved in BCL-6 repression. *Genes Dev* **14**: 1810–1823.
- Johnson RL, Rothman AL, Xie J, Goodrich LV, Bare JW, Bonifas JM, Quinn AG, Myers RM, Cox DR, Epstein EH, et al. 1996. Human homolog of *patched*, a candidate gene for the basal cell nevus syndrome. *Science* **272**: 1668–1671. doi:10.1126/science.272.5268.1668
- Junco SE, Wang R, Gaipa JC, Taylor AB, Schirf V, Gearhart MD, Bardwell VJ, Demeler B, Hart PJ, Kim CA. 2013. Structure of the polycomb group protein PCGF1 in complex with BCOR reveals basis for binding selectivity of PCGF homologs. *Structure* **21**: 665–671. doi:10.1016/j.str.2013.02.013
- Kawauchi D, Taniguchi H, Watanabe H, Saito T, Murakami F. 2006. Direct visualization of nucleogenesis by precerebellar neurons: involvement of ventricle-directed, radial fibre-associated migration. *Development* **133**: 1113–1123. doi:10.1242/dev.02283
- Kawauchi D, Robinson G, Uziel T, Gibson P, Reh J, Gao C, Finkelstein D, Qu C, Pounds S, Ellison DW, et al. 2012. A mouse model of the most aggressive subgroup of human medulloblastoma. *Cancer Cell* **21**: 168–180. doi:10.1016/j.ccr.2011.12.023
- Kenney AM, Cole MD, Rowitch DH. 2003. Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors. *Development* **130**: 15–28. doi:10.1242/dev.00182
- Kessler JD, Hasegawa H, Brun SN, Emmenegger BA, Yang Z-J, Dutton JW, Wang F, Wechsler-Reya RJ. 2009. N-myc alters the fate of preneoplastic cells in a mouse model of medulloblastoma. *Genes Dev* **23**: 157–170. doi:10.1101/gad.1759909
- Kooi IE, Mol BM, Massink MPG, Ameiziane N, Meijers-Heijboer H, Dommering CJ, van Mil SE, de Vries Y, van der Hout AH, Kaspers GJL, et al. 2016. Somatic genomic alterations in retinoblastoma beyond RB1 are rare and limited to copy number changes. *Sci Rep* **6**: 25264. doi:10.1038/srep25264
- Kool M, Jones DTW, Jäger N, Northcott PA, Pugh TJ, Hovestadt V, Piro RM, Esparza LA, Markant SL, Remke M, et al. 2014. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. *Cancer Cell* **25**: 393–405. doi:10.1016/j.ccr.2014.02.004
- Lee EY, Ji H, Ouyang Z, Zhou B, Ma W, Vokes SA, McMahon AP, Wong WH, Scott MP. 2010. Hedgehog pathway-regulated gene networks in cerebellum development and tumorigenesis. *Proc Natl Acad Sci* **107**: 9736–9741. doi:10.1073/pnas.1004602107
- Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. 2012. The sva package for removing batch effects and other unwanted

- variation in high-throughput experiments. *Bioinformatics* **28**: 882–883. doi:10.1093/bioinformatics/bts034
- Mackay A, Burford A, Carvalho D, Izquierdo E, Fazal-Salom J, Taylor KR, Bjerke L, Clarke M, Vinci M, Nandhabalan M, et al. 2017. Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. *Cancer Cell* **32**: 520–537.e5. doi:10.1016/j.ccell.2017.08.017
- Mariño-Enriquez A, Lauria A, Przybyl J, Ng TL, Kowalewska M, Debiec-Rychter M, Ganesan R, Sumathi V, George S, McCluggage WG, et al. 2018. BCOR internal tandem duplication in high-grade uterine sarcomas. *Am J Surg Pathol* **42**: 335–341. doi:10.1097/PAS.0000000000000993
- Northcott PA, Dubuc AM, Pfister S, Taylor MD. 2012. Molecular subgroups of medulloblastoma. *Expert Rev Neurother* **12**: 871–884. doi:10.1586/ern.12.66
- Northcott PA, Buchhalter I, Morrissy AS, Hovestadt V, Weischenfeldt J, Ehrenberger T, Gröbner S, Segura-Wang M, Zichner T, Rudneva VA, et al. 2017. The whole-genome landscape of medulloblastoma subtypes. *Nature* **547**: 311–317. doi:10.1038/nature22973
- Oki S, Ohta T, Shioi G, Hatanaka H, Ogasawara O, Okuda Y, Kawaji H, Nakaki R, Sese J, Meno C. 2018. ChIP-Atlas: a data-mining suite powered by full integration of public ChIP-seq data. *EMBO Rep* **19**: e46255.
- Okonechnikov K, Conesa A, García-Alcalde F. 2016. Qualimap 2: advanced multi-sample quality control for high-throughput sequencing data. *Bioinformatics* **32**: 292–294.
- Oliver TG, Read T-A, Kessler JD, Mehmeti A, Wells JF, Huynh TTT, Lin SM, Wechsler-Reya RJ. 2005. Loss of *patched* and disruption of granule cell development in a pre-neoplastic stage of medulloblastoma. *Development* **132**: 2425–2439. doi:10.1242/dev.01793
- Pajtlér KW, Wei Y, Okonechnikov K, Silva PBG, Vouri M, Zhang L, Brabetz S, Sieber L, Gulley M, Mauermann M, et al. 2019. YAP1 subgroup supratentorial ependymoma requires TEAD and nuclear factor I-mediated transcriptional programmes for tumorigenesis. *Nat Commun* **10**: 3914–3916. doi:10.1038/s41467-019-11884-5
- Paret C, Theruvath J, Russo A, Kron B, Malki El K, Lehmann N, Wingerter A, Neu MA, Gerhold-Ay A, Wagner W, et al. 2016. Activation of the basal cell carcinoma pathway in a patient with CNS HGNET-BCOR diagnosis: consequences for personalized targeted therapy. *Oncotarget* **7**: 83378–83391. doi:10.18632/oncotarget.13092
- Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. 2015. *limma* powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* **43**: e47. doi:10.1093/nar/gkv007
- Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, Brown GD, Gojis O, Ellis IO, Green AR, et al. 2012. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. *Nature* **481**: 389–393. doi:10.1038/nature10730
- Roy A, Kumar V, Zorman B, Fang E, Haines KM, Doddapaneni H, Hampton OA, White S, Bavle AA, Patel NR, et al. 2015. Recurrent internal tandem duplications of BCOR in clear cell sarcoma of the kidney. *Nat Commun* **6**: 8891–8897. doi:10.1038/ncomms9891
- Santiago T, Clay MR, Allen SJ, Orr BA. 2017. Recurrent BCOR internal tandem duplication and BCOR or BCL6 expression distinguish primitive myxoid mesenchymal tumor of infancy from congenital infantile fibrosarcoma. *Mod Pathol* **30**: 884–891. doi:10.1038/modpathol.2017.12
- Schüller U, Heine VM, Mao J, Kho AT, Dillon AK, Han Y-G, Huillard E, Sun T, Ligon AH, Qian Y, et al. 2008. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. *Cancer Cell* **14**: 123–134. doi:10.1016/j.ccr.2008.07.005
- Schuster AE, Schneider DT, Fritsch MK, Grundy P, Perlman EJ. 2003. Genetic and genetic expression analyses of clear cell sarcoma of the kidney. *Lab Invest* **83**: 1293–1299. doi:10.1097/01.LAB.0000087850.69363.59
- Sturm D, Orr BA, Toprak UH, Hovestadt V, Jones DTW, Capper D, Sill M, Buchhalter I, Northcott PA, Leis I, et al. 2016. New brain tumor entities emerge from molecular classification of CNS-PNETs. *Cell* **164**: 1060–1072. doi:10.1016/j.cell.2016.01.015
- Tamayo-Orrego L, Charron F. 2019. Recent advances in SHH medulloblastoma progression: tumor suppressor mechanisms and the tumor microenvironment. *F1000Res* **8**: 1823. doi:10.12688/f1000research.20013.1
- Tamayo-Orrego L, Wu C-L, Bouchard N, Khedher A, Swikert SM, Remke M, Skowron P, Taylor MD, Charron F. 2016. Evasion of cell senescence leads to medulloblastoma progression. *Cell Rep* **14**: 2925–2937. doi:10.1016/j.celrep.2016.02.061
- Tara S, Isshiki Y, Nakajima-Takagi Y, Oshima M, Aoyama K, Tanaka T, Shinoda D, Koide S, Saraya A, Miyagi S, et al. 2018. Bcor insufficiency promotes initiation and progression of myelodysplastic syndrome. *Blood* **132**: 2470–2483. doi:10.1182/blood-2018-01-827964
- Tiberi L, Bonnefont J, van den Ameele J, Le Bon S-D, Herpoel A, Bilheu A, Baron BW, Vanderhaeghen P. 2014. A BCL6/BCOR/SIRT1 complex triggers neurogenesis and suppresses medulloblastoma by repressing Sonic Hedgehog signaling. *Cancer Cell* **26**: 797–812. doi:10.1016/j.ccell.2014.10.021
- Udaka YT, Packer RJ. 2018. Pediatric brain tumors. *Neurol Clin* **36**: 533–556. doi:10.1016/j.ncl.2018.04.009
- Ueno-Yokohata H, Okita H, Nakasato K, Akimoto S, Hata J-I, Koshinaga T, Fukuzawa M, Kiyokawa N. 2015. Consistent in-frame internal tandem duplications of BCOR characterize clear cell sarcoma of the kidney. *Nat Genet* **47**: 861–863. doi:10.1038/ng.3338
- Vewinger N, Huprich S, Seidmann L, Russo A, Alt F, Bender H, Sommer C, Samuel D, Lehmann N, Backes N, et al. 2019. IGF1R is a potential new therapeutic target for HGNET-BCOR brain tumor patients. *Int J Mol Sci* **20**: 3027. doi:10.3390/ijms20123027
- Vogelstein B, Kinzler KW. 1993. The multistep nature of cancer. *Trends Genet* **9**: 138–141. doi:10.1016/0168-9525(93)90209-Z
- Wamstad JA, Bardwell VJ. 2007. Characterization of Bcor expression in mouse development. *Gene Expr Patterns* **7**: 550–557. doi:10.1016/j.modgep.2007.01.006
- Wamstad JA, Corcoran CM, Keating AM, Bardwell VJ. 2008. Role of the transcriptional corepressor Bcor in embryonic stem cell differentiation and early embryonic development. *PLoS One* **3**: e2814. doi:10.1371/journal.pone.0002814
- Wang H, Wang L, Erdjument-Bromage H, Vidal M, Tempst P, Jones RS, Zhang Y. 2004. Role of histone H2A ubiquitination in Polycomb silencing. *Nature* **431**: 873–878. doi:10.1038/nature02985
- Wang Z, Gearhart MD, Lee Y-W, Kumar I, Ramazanov B, Zhang Y, Hernandez C, Lu AY, Neuenkirchen N, Deng J, et al. 2018. A non-canonical BCOR-PRC1.1 complex represses differentiation programs in human ESCs. *Cell Stem Cell* **22**: 235–251.e9. doi:10.1016/j.stem.2017.12.002
- Waszak SM, Robinson GW, Gudenat BL, Smith KS, Forget A, Kojic M, Garcia-Lopez J, Hadley J, Hamilton KV, Indersie E, et al. 2020. Germline elongator mutations in sonic hedgehog

Kutscher et al.

- medulloblastoma. *Nature* **580**: 396–401. doi:10.1038/s41586-020-2164-5
- Wong MK, Ng CCY, Kuick CH, Aw SJ, Rajasegaran V, Lim JQ, Sudhanshi J, Loh E, Yin M, Ma J, et al. 2018. Clear cell sarcomas of the kidney are characterised by *BCOR* gene abnormalities, including Exon 15 internal tandem duplications and *BCOR-CCNB3* gene fusion. *Histopathology* **72**: 320–329. doi:10.1111/his.13366
- Worst BC, van Tilburg CM, Balasubramanian GP, Fiesel P, Witt R, Freitag A, Boudalil M, Previti C, Wolf S, Schmidt S, et al. 2016. Next-generation personalised medicine for high-risk paediatric cancer patients—the INFORM pilot study. *Eur J Cancer* **65**: 91–101. doi:10.1016/j.ejca.2016.06.009
- Yang Z-J, Ellis T, Markant SL, Read T-A, Kessler JD, Bourbonoulas M, Schüller U, Machold R, Fishell G, Rowitch DH, et al. 2008. Medulloblastoma can be initiated by deletion of patched in lineage-restricted progenitors or stem cells. *Cancer Cell* **14**: 135–145. doi:10.1016/j.ccr.2008.07.003
- Zhang Y, Liu T, Meyer CA, Eeckhoutte J, Johnson DS, Bernstein BE, Nussbaum C, Myers RM, Brown M, Li W, et al. 2008. Model-based analysis of ChIP-seq (MACS). *Genome Biol* **9**: R137–R139. doi:10.1186/gb-2008-9-9-r137
- Zuckermann M, Hovestadt V, Knobbe-Thomsen CB, Zapatka M, Northcott PA, Schramm K, Belic J, Jones DTW, Tschida B, Moriarity B, et al. 2015. Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling. *Nat Commun* **6**: 7391. doi:10.1038/ncomms8391
- Zuckermann M, Hlevnjak M, Yazdanparast H, Zapatka M, Jones DTW, Lichter P, Gronych J. 2018. A novel cloning strategy for one-step assembly of multiplex CRISPR vectors. *Sci Rep* **8**: 17499. doi:10.1038/s41598-018-35727-3

Functional loss of a noncanonical BCOR–PRC1.1 complex accelerates SHH-driven medulloblastoma formation

Lena M. Kutscher, Konstantin Okonechnikov, Nadja V. Batora, et al.

Genes Dev. 2020, **34**: originally published online August 20, 2020

Access the most recent version at doi:[10.1101/gad.337584.120](https://doi.org/10.1101/gad.337584.120)

Supplemental Material <http://genesdev.cshlp.org/content/suppl/2020/08/19/gad.337584.120.DC1>

References This article cites 58 articles, 14 of which can be accessed free at:
<http://genesdev.cshlp.org/content/34/17-18/1161.full.html#ref-list-1>

Creative Commons License This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see <http://genesdev.cshlp.org/site/misc/terms.xhtml>). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International) as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

Email Alerting Service Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).